Pictet Asset Management Holding SA Has $84.79 Million Holdings in Incyte Corporation $INCY

Posted by Stanley Muller on Jun 30th, 2026

Pictet Asset Management Holding SA decreased its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 30.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 916,188 shares of the biopharmaceutical company’s stock after selling 399,478 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.46% of Incyte worth $84,788,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of INCY. Geode Capital Management LLC grew its position in shares of Incyte by 11.3% in the 4th quarter. Geode Capital Management LLC now owns 4,993,012 shares of the biopharmaceutical company’s stock valued at $491,500,000 after buying an additional 506,842 shares during the last quarter. Invesco Ltd. increased its stake in shares of Incyte by 13.2% in the fourth quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock valued at $343,105,000 after buying an additional 405,611 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Incyte by 13.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,103,946 shares of the biopharmaceutical company’s stock worth $263,246,000 after acquiring an additional 373,298 shares during the last quarter. Morgan Stanley lifted its stake in shares of Incyte by 0.9% in the fourth quarter. Morgan Stanley now owns 2,663,823 shares of the biopharmaceutical company’s stock worth $263,106,000 after acquiring an additional 23,087 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Incyte by 7.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 2,480,793 shares of the biopharmaceutical company’s stock worth $245,028,000 after acquiring an additional 161,405 shares during the period. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte Price Performance

Shares of INCY opened at $114.66 on Tuesday. Incyte Corporation has a 52-week low of $66.83 and a 52-week high of $115.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68. The business’s 50 day moving average price is $99.67 and its two-hundred day moving average price is $99.33. The firm has a market cap of $22.91 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 1.11 and a beta of 0.79.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.38 by $0.43. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.22 billion. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company’s quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.16 EPS. On average, equities analysts anticipate that Incyte Corporation will post 6.61 EPS for the current year.

Analyst Ratings Changes

INCY has been the topic of several analyst reports. Stifel Nicolaus set a $123.00 target price on Incyte in a report on Tuesday, June 9th. TD Cowen restated a “hold” rating on shares of Incyte in a research report on Tuesday, June 9th. Truist Financial upped their price objective on shares of Incyte from $103.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Barclays reiterated an “overweight” rating on shares of Incyte in a research report on Tuesday, March 24th. Finally, Citigroup reissued a “market perform” rating on shares of Incyte in a research note on Tuesday, June 2nd. Eight analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $107.85.

Check Out Our Latest Stock Report on Incyte

Insider Transactions at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a total value of $1,801,365.50. Following the completion of the sale, the insider directly owned 262,692 shares in the company, valued at approximately $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is currently owned by corporate insiders.

Incyte Profile

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.